tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Bright Minds assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Bright Minds (DRUG) with an Overweight rating and no price target Bright Minds’ lead asset, BMB-101, is a highly selective 5-HT2C receptor agonist in developmental and epileptic encephalopathies and absence epilepsy, the analyst tells investors in a research note. BMB-101 may deliver improved efficacy, safety, and durability vs. competitors, the firm says.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1